{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:42Z","timestamp":1786119462425,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/mcg.0b013e3181cb4233","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T05:37:43Z","timestamp":1269581863000},"page":"385","source":"Crossref","is-referenced-by-count":30,"title":["Saccharomyces boulardii Plus Rifaximin in Mesalamine-intolerant Ulcerative Colitis"],"prefix":"10.1097","volume":"44","author":[{"given":"Mario","family":"Guslandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210305","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1365-2036.1996.92264000.x","article-title":"Adverse events in patients treated with 5-aminosalicylic acid: 1993 to 1994 pharmacovigilance report for pentasi in France","volume":"10","author":"Marteau","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-18-20210305","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ibd.20525","article-title":"Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel disease","volume":"14","author":"Vanderpool","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R3-18-20210305","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2006.10.001","article-title":"Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes","volume":"131","author":"Dalmasso","year":"2006","journal-title":"Gastroenterology"},{"key":"R4-18-20210305","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.3748\/wjg.v12.i37.5941","article-title":"Probiotics and prebiotics in chronic inflammatory bowel diseases","volume":"12","author":"Ewashuck","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R5-18-20210305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.MIB.0000215092.85116.6c","article-title":"Rifaximin for active ulcerative colitis","volume":"12","author":"Guslandi","year":"2006","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCG.0b013e3181cb4233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:12:54Z","timestamp":1786039974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-201005000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e3181cb4233","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}